Q-omics provides the consensus-scored FOLR2 profile across patient tissues and cancer cell-line models. FOLR2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, FOLR2 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, FOLR2 protein abundance shows 26,353 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUSC, KIRC, and LSCC as cancer lineages where FOLR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOLR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOLR2 survival associations across molecular data types. FOLR2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOLR2 RNA expression–survival associations across cancer types. High FOLR2 expression shows unfavorable associations in LUSC and STAD, but favorable associations in SCLC, LGG, SKCM and LUAD. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for FOLR2 RNA expression.
This table summarizes FOLR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for FOLR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOLR2 shows lower tumor expression in COAD, BLCA, LUSC, BRCA and KICH and higher tumor expression in KIRC. The KIRC box plot shows higher FOLR2 RNA expression in tumor versus normal tissue (log2 FC = +1.744, t-test p < 0.001).
This table shows molecular features associated with FOLR2 in patient tissues and cancer cell lines. In patient samples, FOLR2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FOLR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
